Member Info for RMFatGB

Did anyone take the time to view the Hairy Bikers and David Myers battle with Cancer and Chemo?, https://www.bbc.co.uk/programmes/m001tlv4

I found the programme to be very informative and it really highlights the issues with Cancer treatments, (Chemo'). If only there was a way to offer a greater dose of Chemo’ (Dox) with fewer side effects, there may be a way saving lives that would otherwise be lost. Wishing Dave Myers and his family all the very best for the future.

Avacta has a solution to a known problem and there will be a number of very interested parties. It is worth another look at the Avacta RNS from 13th December 2023, https://avacta.com/als-6000-101-phase-1a-three-weekly-dose-escalation-safety-study-data/

Wishing everyone a Very Happy, Healthy & Prosperous New Year.

Sit tight & GLA

@meldrew44

30 Jun 2023 07:30

RNS Number : 5279E

ADVANCED ONCOTHERAPY PLC

At the request of the Company trading on AIM for the under-mentioned securities was temporarily suspended from 30/06/2023 7:30am, pending clarification of the Company's financial position.

@meldrew44

They have been suspended for some time and we are unable to trade. Is there a time limit on how long a share can be suspended before being deemed worthless?

https://aim-watch.com/project/trading-suspensions-overview/ Finally, when it comes to AIM, should the securities of any company be suspended for six months, the securities will be cancelled from trading unless an extension has been granted.

Perhaps we will be enlightened soon?

The link without the end bracket - www.bbc.co.uk/programmes/m001tlv4

My wife and I are preparing to host family and friends over Christmas. We sat down for a tea break yesterday afternoon and turned on television. The programme that came on was The Hairy Bikers: Coming Home for Christmas.

For those who do not know, the Hairy Bikers are David Myers and Si King, two best friends who ride motor bikes and cook for a living. Dave Myers was struck by cancer and the programme shows some of his treatment and the process of recovery.

Dave is a man in his 60’s with a healthy appetite. The chemo came with side effects, (loss of appetite, mouth ulcers, loss of hair, loss of weight, strength and balance). Part of the programme shows Dave going through physio and aiming to get back to his family and back on the road with his mate Si’.

The programme brings home the horrors of cancer and the impact on the sufferer, their family and friends. If you have not viewed the programme, it is worth a look and there are some festive treats and fun, (available on the BBC - https://www.bbc.co.uk/programmes/m001tlv4)

Having watched the programme, it brings home the need for AVA6000 and a platform (pre|CISION™) that can be used with other toxins to offer life-saving cancer treatments with minimal side effects.

While some may worry about their investment and the share price, consider what is most important. For me it’s health, happiness, friends and family.

Wishing you all a Very Merry Christmas and a Happy and Healthy New Year.

All the very best for 2024

I have been invested in Avacta for over 10 years. I attended the most recent AGM and had discussions with AS, EF and FMcL. I have followed the progress made by Avacta and am confident in both the science and my investment.

I read through the posts on LSE on occasion, however, I have found myself putting more accounts in the filter box. My filter box recently reached 100 contacts and I can now read the content that has some value. If there are accounts which annoy, use the filter box and let’s focus on the positive at the very exciting time.

BIG NEWS is on the way, GLA

And, less than 24 hours later, over 6,500 views.

Not all RNS come out at 7am

Https://avacta.com/director-appointment-2/

"Shaun Chilton was most recently Chief Executive Officer (“CEO”) of the formerly London-listed Clinigen Group plc (“Clinigen”). During his tenure, the company expanded through both an organic and a buy-and-build strategy. The Company was eventually sold to Triton Partners for a total consideration of c.£1.3 billion in April 2022".

Interesting, .... GLA

200K shares traded this morning and we are down £0.05 (3.70%).

Short term holders possibly expecting an RNS and have panicked when it didn’t arrive this morning. LTH’s know what we are sitting on and there could be several RNS during Q4.

As ever, sit tight, there are plenty of days left in Q4.

GLA

PS: Wednesday and Thursdays are good RNS days

Global Oncology Trends 2023: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2023

- Oncology trial starts remained at historically high levels in 2022, up 22% from 2018.

- Spending on cancer medicines is expected to reach $375Bn globally by 2027, up by more than 90% from $196Bn in 2022.

- Emerging biopharma companies (EBP’s) led innovation in oncology in 2022 and account for 71% of the pipeline.

Cancer Research UK: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/how-clinical-trials-are-planned-and-organised/how-long-it-takes-for-a-new-drug-to-go-through-clinical-trials

All new drugs and treatments have to be thoroughly tested before they are licensed and available for patients.

There is no typical length of time it takes for a drug to be tested and approved. It might take 10 to 15 years or more to complete all 3 phases of clinical trials before the licensing stage.

Avacta: https://avacta.com/therapeutics/precision/

Avacta is now in clinic with its lead pre|CISION™ programme, AVA6000, a tumour-activated form of doxorubicin.

With AVA6000, doxorubicin is rendered inert until the substrate is cleaved in the tumour microenvironment. In this way, systemic exposure to the therapy is dramatically reduced, and the safety and therapeutic window of powerful anti-cancer treatments is improved.

The high modularity of the pre|CISION™ platform offers the potential to use the precision substrate on a range of therapeutic agents (toxins) for the next generation of tumour microenvironment activated drug technologies.

Conclusions:

- Big Pharma spend $Bn’s each year developing new oncology treatments.

- The development and approvals cycle can be 10 to 15 years.

- Spending on cancer medicines is expected to reach $375Bn by 2027.

- Most new innovations are coming from Emerging biopharma companies, (EBP’s).

- Big Pharma is making licencing deals with EBP’s like Avacta.

- In some cases, Big Pharma is acquiring EBP’s like Avacta.

- There is going to be a paradigm shift in how chemotherapy is delivered to cancer patients

Expecting BIG NEWS during Q4, 2023.

Sit tight and GLA.

Perhaps he is expecting Big Pharma to make the deal soon and he will no longer be required at Avacta.

Looking for his next opportunity?

There are long established accounts on here that represent LTH’s.

LTH’s, who are well researched, who attended the AGM, who have spoken with Alastair Smith, Fiona McLaughin, Eliot Forster and other member of the Avacta team understand the following:

- Avacta’s pre|CISION™ is a PLATFORM and it works.

- There are two pre|CISION™ products (AVA6000 & AVA3996) currently coming through clinical trials.

- Avacta’s pre|CISION™ platform offers multiple opportunities for other lifesaving products and licencing/partnering agreements.

- With Avacta’s pre|CISION™ platform, we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.

- Avacta is in discussion with Big Pharma, (industry networking, conferences, private consultations).

- Avacta as a company (stock) is undervalued and this will change in the coming months, (Q4?).

To the LTH’s, hold tight and wait for the news (Phase 1a data) that we know is coming soon.

GLA.

PS: Forgot to mention: Funded well in to 2024, FDA granted AVA6000 ODD, Dr. William Tap involved, moving to a 2 week study, etc, etc, etc.

@Kevinl1977

Interesting read and what all LTH's expecting. GLA

Avacta (LON: AVCT)

Avacta enjoys, by some margin, the most dedicated retail investor base on AIM. There are some good reasons for this — its flagship clinical trial candidate AVA6000 is delivering some frankly astounding results for a phase 1 trial — and a company attempting to deliver chemotherapy without side effects will deservedly enjoy investor devotion.

November will almost certainly see Avacta release the hard numbers for Phase 1A — and it’s this data which could start to see research platforms increase the likelihood of success from the standard 10% to a more realistic 40%+.

Investors questioning why this data isn’t published yet should understand that from a trust perspective, the company gets one shot at a first impression: any mistakes, no matter how small, would require a rectification. This would be a disaster from a PR perspective, when you have a company attempting to convince the wider investing public that it can deliver such an extraordinary medical advancement.

Fortunately, it seems that CEO Alastair Smith understands the need to be careful when starting to engage with the mainstream media. The other facet to consider is financial; while Avacta has multiple funding options open, including non-dilutive, the company will need access to significant cash to deliver the next clinical trial phase.

It seems inevitable that a tie-up between Avacta and a pharma major is coming down the tracks — if nothing else, the company simply does not have the financial firepower to engage in logistics such as mass manufacture and transport of its treatments.

I suspect that the favoured partner will be Novartis — apart from its large cash position and appetite for merger activity, its head of innovation of Global Drug Development, Janet Munro, recently issued a ‘personal view’ on LinkedIn concurring with Smith that AVA6000 may very well be a ‘paradigm shift.’

Of course — and I’ve made this point before — Avacta is still in the early days. No biotech, no matter how promising, is a sure thing. But the risk-reward ratio remains very attractive, even If you could have picked up shares for less than £1 a few short months ago.

@jive_turkey

"It's also at 17% above the UK price"

Exchange Rates (US$)?

Good day today. Perhaps an RNS is coming soon?

GLA

The quiet before the storm (BIG RNS)?

1.25% per month over 4 months is 6%.

Perhaps about to suspend Avacta with news of a Big Pharma Bid?

Forgot to mention, down £ 0.01 at 14:00. The drop occurred in the last hour. Probably back up again by 16:30 in RNS anticipation.

Sit tight & GLA.